Published in Hepatitis Weekly, September 7th, 1998
The findings of researcher Stephen J. Polyak and colleagues could have significant clinical impact.
"The clinical importance of the current study is the demonstration of significant alterations in the hepatitis C virus (HCV) genome in nonresponsive or relapse patients infected with HCV-1 who were treated with interferon via the standard thrice-weekly regimen," Polyak et al. wrote ("Evolution of HCV Quasispecies in Hypervariable Region 1 and the Putative Interferon...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.